Medical education - Communicating best practice

Atherosclerosis

Volumn 143, Issue SUPPL. 1, 1999, Pages

  Poulter, N R ^a  

^a Dept Clin Pharmacol Imp C ^*  (United Kingdom)

Author keywords

Cardiovascular mortality; Coronary heart disease (CHD); Modifiable risk factors

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN;

ACUTE HEART INFARCTION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONFERENCE PAPER; DOSE RESPONSE; DYSLIPIDEMIA; FRANCE; GERMANY; HEALTH SURVEY; HIGH RISK PATIENT; HYPERTENSION; ISCHEMIC HEART DISEASE; ITALY; MEDICAL EDUCATION; MEDICAL PRACTICE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; UNITED KINGDOM;

CARDIOLOGY; CORONARY DISEASE; EDUCATION, MEDICAL; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES; PREVENTIVE MEDICINE; RISK FACTORS;

EID: 0033017177     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00102-1     Document Type: Conference Paper

References (31)

1. British Heart Foundation Health Promotion Research Group. Coronary Heart Disease Statistics. 1997 ed. London, UK: British Heart Foundation.
2. Poulter NR, Sever PS, McG Thom. CVD: Practical issues for prevention. St Albans: Caroline Black, 1996.
3. Kannel WB, Wilson PW An update on coronary risk factors. Med Clin N Am. 79(5):1995;951-971.
4. Stamler J, Wentworth D, Neaton JD for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? J Am Med Assoc. 256:1986;2823-2828.
5. Assmann G, Cullen P, Schulte H The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 19(Suppl A):1998;A2-11.
6. Shaper AG, Pocock SJ Risk factors for ischaemic heart disease in British men. Br Heart J. 57:1987;11-16.
7. Poulter NR Is one risk factor more important than another? Risk. 1(2):1993;4-9.
8. Ravnskov U Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. Br Med J. 305:1992;15-19.
9. Chapman S The role of doctors in promoting smoking cessation. Br Med J. 307:1993;518-519.
10. Colhoun HM, Poulter NR Blood pressure screening, management and control in England; results from the Health Survey for England 1994. J Hypertens. 16:1998;747-753.
11. Burt VL, Cutler JA, Higginas Met al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension. 26:1995;60-69.
12. Gozlan M European drug consumption. Lancet. 344:1994;1695-1696.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994:344;1383-1389.
14. Prescott-Clarke T, Primatesta P, editors. Health Survey of England 1995. London: HMSO, 1997.
15. Dong W, Erens B, editors. Scottish Health Survey 1995. Edinburgh: The Stationery Office, 1997.
16. World Health Statistics Annual 1994. Geneva: WHO, 1995.
17. Steptoe A, Wardle J What the experts think: a European survey of expert opinion about the influence of lifestyle on health. Eur J Epidemiol. 10:1994;195-203.
18. Bowker TJ, Clayton TC, lngham JEet al. A British Cardiac Society Survey of the Potential for Secondary Prevention of Coronary Diseases - 'ASPIRE'. Heart. 75:1996;334-342.
19. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997:18;1569-1582.
20. Shepherd J, Alcalde V, Befort P-A, Boucher B, Erdmann E, Gutzqiller Fet al. (HELP Study Group) International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. J Cardiovasc Risk. 4:1997;373-384.
21. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KAet al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 335:1990;827-828.
22. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97:1998;946-952.
23. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J. 19:1998;1434-1503.
24. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Atherosclerosis. 140(2):1998;199-270.
25. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. J Hypertens. 16(10):1998;1407-1414.
26. Wood D, Durrington P, Poulter N, McInnes G, Reece A, Wray W Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 80(Suppl 2):1998;S1-S29.
27. Worral G, Chaulk P, Freake D The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. Can Med Assoc J. 156:1997;1705-1712.
28. Chalmers J Guidelines and consensus statements: their use and impact. J Human Hypertens. 9:1995;37-40.
29. Jackson R, Feder G Guidelines for clinical guidelines. Lancet. 317:1998;427-428.
30. Hunink MAM, Goldman L, Tosteson ANA, Mittleman MA, Goldman PA, Williams LW The recent decline in mortality from coronary heart disease, 1980-1990. J Am Med Assoc. 277:1997;535-542.
31. Ueshima H, Tatara K, Asakura S, Okamoto M. Declining trends in blood pressure level and the prevalence of hypertension, and changes in related factors in Japan, 1956-1980. J Chron Dis 40:137-147.